Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.

Dr. E. Anne Peterson, MD, MPH Assistant Administrator, Bureau for Global Health, USAID Sustainable Investment and Donor Coordination Stop TB Partners Forum.

ARIAtlas.org. Global Impact TB causes nearly two million deaths a year, making it the world’s seventh most common cause of mortality. More than two billion.

BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.

Stepping up the Pace Together Dynamic Partnerships Across Community, Academic and Policy Sectors Kevin Miles - Manager of Health Programmes.

NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.

Fast-track to ending AIDS in Zimbabwe: opportunities

January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.

Opportunities & Challenges: Expanding Access to Hepatitis C Treatment Gregg Alton Executive Vice President, Corporate & Medical Affairs.

Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.

The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.

Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.

HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.

AIDS Vaccine R&D (post-AIDSVAX®). R&D challenges Products in development Funding AIDS vaccine R&D Access and advocacy.

T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.

Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.

PREVENTING RELAPSE Lee B. Reichman, MD, MPH Northeast TB Controllers Meeting October 24, 2006 Princeton, New Jersey.

ART Program of the HIV Vaccine Trials Network Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

Group Discussion Guyana, The Bahamas T & T, Jamaica Barbados, Haiti Suriname, Curacao.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

DoHDST. South African AIDS Vaccine Initiative (SAAVI)  Established in late1999 by the South African government.  Based at the Medical Research Council.

Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body TT

6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,

1 Global Health Research How the private sector contribute Bergen, 22. September 2004 Birger Sørensen, President CEO Bionor Immuno AS.

OCTOBER 2014 TREATMENT ACTION GROUP MIKE FRICK. Annual Global Plan Research Funding Targets versus 2013 Funding $600,000,000 $800,000,000 $400,000,000.

British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, FRCPC, FCCP, FRSC Director, BC-Centre for Excellence on HIV/AIDS, Providence Health.

HIV/ AIDS Right now, 1 out of every 300 people in the United States has HIV, the virus that causes AIDS.

2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.

Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

Tuberculosis is a global public health issue. The Role of the International Agencies Introduction TB which stands for Tuberculosis is a rather infectious.

1 Global Health Research How the private sector contribute Bergen, 22. September 2004 Birger Sørensen, Adm.dir. Bionor Immuno AS.

HANC and Community Partners Overview November 20, 2007 Michael Petillo, Project Coordinator.

Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.

“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.

1 Medication Development for Treatment of Drug Dependence Donald R. Wesson, MD Consultant, CNS Medications Development Chairman, ASAM Medications Development.

What Is Ethics Review. In Groups More than 33 million people today have HIV and risk contracting AIDS if they do not receive effective inhibitor medications.

ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.

CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals.

Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.

CLINICAL TRIALS.

Vaccine Company Perspective Dr Gaurav Gupta, ZYDUS CADILA

20:20 Vision Making new and old money work better

ILO Programme on HIV and AIDS and the world of work,

MEP Interest Group on Brain, Mind and Pain

Prevention Solutions for the Next Generation: Highlighting Adolescent Research in the NIH HIV/AIDS Clinical Trials Networks and the Adolescent Trials Network.

HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.

What’s Next – and When: An Update on Injectable Prevention

Big Data Analyses: The Cancer Moonshot

Facilitating development and adaptation of the right tools

INNOVATION IN THE DEVELOPMENT OF NEW DRUGS AND CREATIVE SOLUTIONS TO ENSURING EARLY AND ENHANCED ACCESS Paul Stoffels, M.D. Chief Scientific Officer,

Expanding ARV treatment in developing countries: Issues and Prospects

Richard hayes London school of hygiene & Tropical Medicine

AIDS supplement.

Katharina Hauck On behalf of the HPTN 071 Study Team

The Industrial Strategy Challenge Fund & the Focus on Life Sciences

HIV, History, and Immunity

Private sector involvement IPM-Tibotec case study

A bold new approach to medical education

Trial Funding and Engagement: The NIH Sponsored CTSA Program

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Every Mother, Every Child: Closing the Gaps in HIV Management

Prevention Solutions for the Next Generation: Highlighting Adolescent Research in the NIH HIV/AIDS Clinical Trials Networks and the Adolescent Trials Network.

HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE

Presentation transcript:

Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson

Disclosure of Speaker Interests Relation relevant to the meeting Company name Vice Chair of the Executive Committee and Chief Scientific Officer Johnson & Johnson

Industry Has Delivered Significant Impact In HIV From clinical end points to biomarker- based approval 20 new drugs in 20 years From 20-30 pills a day to one pill a day From 2 years life expectancy in 1983 to near normal life expectancy today 21.7 mm people on therapy globally through innovative access models Projection: 300 Million years of life saved http://www.who.int/hiv/mediacentre/news/global-aids-update-2016-news/en/

HIV Remains a Critical, Growing Global Concern The Interventions More than 20 Antiretroviral Drugs and combinations Diagnostics : CD4, Viral Load, Resistance Testing The Challenges Life-long therapy (30-50 years): major manufacturing challenge Highly mutable virus leading to resistance Supply Chain, Logistics, Funding 36.7M people living with HIV 2.1M new HIV infections annually 1.1M deaths annually from AIDS, 70% in Africa What’s Needed: Innovation in Therapy, Access, Prevention, and Cure Source: World Health Organization (WHO), April 2017.

ASM 2011 2/23/2019 8:40 AM Working Together To Make HIV History: A story of Public Private Partnership Treatment: % Collaboration with NIH, Industry, Governments, Regulators, Patients, Civil Society Prevention: Collaboration with IPM, patients, local governments Collaboration with ViiV Healthcare Gates Foundation NIH-NIAID-DAIDS NIH Ragon Institute BIDMC/Harvard MHRP HVTN IAVI 4x3_ASM_2011_Weldon_Close_04-28-11_v14.pptx

Status of HIV Vaccine Strong protection in non-human primates APPROACH study correlates of protection Nearly 400 people Durable protection after 1 year of vaccination Phase 2b IMBOKODO trial: >400 / 2600 recruited Global collaboration: Gates Foundation Beth Israel Deaconess Medical Center, Harvard Medical School US Military HIV Research Program NIAID/NIH Ragon Institute IAVI HVTN / MRC SA http://www.who.int/hiv/mediacentre/news/global-aids-update-2016-news/en/